Skin Cancer – Melanoma and the Clinical Oncology Service

Skin Cancer - Clinical Oncology Service

The Christie NHS Foundation Trust
Operational Structure

Melanoma services are provided by the Skin Cancer Group. Dermatology is provided on hub-and-spoke basis from Salford Royal Foundation Trust. Plastic surgery is provided by UHSM and The Christie NHS Foundation Trust (approximately 30/70 % split). Specialist plastic interventions, i.e. sentinel node biopsy, lymphadenectomy, electro-chemotherapy) are provided only at The Christie Hospital NHS Foundation Trust. Oncology services are provided at The Christie Hospital NHS Foundation Trust with some patients receiving palliative radiotherapy at Oldham. Patients requiring stereotactic radiosurgery for brain metastasis are treated at Christie at Salford.

The specialist skin MDT is coordinated by Salford Royal Foundation Trust. This meets by teleconference alternate weeks. The vast majority of melanoma patients are contributed by the Christie team.

Personnel - Melanoma

<table>
<thead>
<tr>
<th>Consultants</th>
<th>Dr Paul Lorigan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Nurse Specialist</td>
<td>Mrs Caroline Owens</td>
</tr>
<tr>
<td>Nurse Clinician</td>
<td>Mrs Jackie Hodgetts</td>
</tr>
<tr>
<td>Research team</td>
<td>Sharon Woolley</td>
</tr>
<tr>
<td></td>
<td>Elaine Mason</td>
</tr>
<tr>
<td></td>
<td>Sam Corlett</td>
</tr>
<tr>
<td></td>
<td>Pamela Hewitt</td>
</tr>
<tr>
<td></td>
<td>Kirsty Ewing</td>
</tr>
<tr>
<td></td>
<td>Smita Odedra</td>
</tr>
<tr>
<td>Clinical Fellows</td>
<td>Dr Alberto Fusi</td>
</tr>
<tr>
<td></td>
<td>Dr Samantha Bowyer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consultants</th>
<th>Dr Andrew Sykes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Agata Rembielak</td>
<td>Dr Ernest Allan</td>
</tr>
<tr>
<td>Dr Lip Lee</td>
<td>Dr Margaret Harris</td>
</tr>
<tr>
<td>Dr Laura Pemberton</td>
<td></td>
</tr>
</tbody>
</table>

Personnel – Clinical Oncology
Activity – Clinical Oncology

459 new patients were seen in the skin oncology clinic from 1st January 2014 to 31st December 2014.

Of these 50 cases were melanoma (15 adjuvant, 35 palliative) and 209 were non-melanoma. A further 150 patients were seen in other clinics.

Two consultants, Dr Sykes and Dr Rembielak see the majority of cases of skin cancer treated with radiotherapy. Patients are seen through the skin oncology clinic on a Monday afternoon. This operates in parallel with Dr Lorigan's melanoma clinic and plastic surgery clinics. Dr Harris, Dr Pemberton and Dr Lee also treat a number of cases of non-melanoma skin cancer from their peripheral clinics and Dr Allan treats patients with both PDT and brachytherapy. It is likely the Dr Allan will retire in the next 18 months and future of the PDT service is uncertain. Dr Rembielak will take over the brachytherapy service.

The majority of these patients were treated with radiotherapy. Melanoma systemic therapy is delivered by Dr Lorigan while very little chemotherapy is given for non-melanoma skin cancer. The exceptions are vismodegib, for advanced basal cell carcinoma and bleomycin for electro-chemotherapy. In the last 12 months 11 patients were started on vismodegib.

Activity – Melanoma

765 new referrals for melanoma seen by surgical team which represents an approximate 10% year on year increase since 2010. 250 new patients seen by Medical Oncology (120 advanced disease, 130 high risk primary). 1216 systemic therapy treatments given in 2013-2014; up 40% on previous year.

Service Development 2013/14

The Christie melanoma service provides a state of the art research based clinical service, linked closely with the CRUK Manchester Institute. The group remains a major contributor to pivotal clinical trials which define new standards of care for patients with advanced disease.

We recently launched our team website: www.christie.nhs.uk/melanoma which provides useful information to patients, carers and those enquiring about clinical trials. In 2013 we held an open access meeting for patients, carers and the general public at the Manchester Museum which provided advice on the risk of melanoma, prevention, advances in treatment and new research in this area. This was well attended and reviewed.
During the year 13/14, commissioning of a service for the provision of Electrochemotherapy, a new and innovative treatment for the palliative management of cutaneous metastases was achieved.

We are submitting a case for a clinical nurse specialist in advanced melanoma to oversee patient-pathways in this difficult area.

The Christie led on publication of consensus statement on imaging follow-up of patients with high risk melanoma which was published in 2014.
Publications 2014


Grant Income:
CRUK - PIANO study £87,000
Christie Charity - PIANO study translational research £103,000
PERM Study – CTAAC approved £80,000

Research and Clinical Audit activity.

Original data were presented by members of the melanoma team at the following meetings: American Society of Clinical Oncology, American Society for Cancer Research, European Society of Medical Oncology, Society for Melanoma Research, European post-ASCO meeting, UK National Cancer Research Institute meeting, European Society for Dermatology Oncology, and Melanoma Focus.

Dr Lorigan was senior author on AVASTM UK adjuvant trial which recruited over 1,300 patients and was published in 2014.
We recently published the results of a study of more than 450 patients looking at anxiety and information needs in patients with resected melanoma. The study was funded by The Christie Charity and carried out by St James Hospital Leeds and the Christie.

Recently completed and ongoing audits include audits of NICE approved systemic therapy (ipilimumab and vemurafenib), toxicity with targeted therapy in older patients, audit of mucosal melanoma treatment outcomes, effectiveness of CT scanning as follow-up in high risk patients, effects on referral for sentinel lymph node biopsy of a change in criteria for stage 1b melanoma, the prognostic value of the ratio of Breslow thickness to skin thickness, audit of discussion and communication of prognosis in patients with advanced melanoma.

**Trials**

**Open**

An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma

A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma

A Phase I/II trial of SCiB1, a DNA immunotherapy, in the treatment of patients with malignant melanoma

**In Set up**

A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma
A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma

An observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European Expanded Access Programme in pretreated patients with advanced (unresectable or metastatic) melanoma (CA184367 study)

A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal Antibody

Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group.

PLX3397 KIT in Acral and Mucosal Melanoma

A Phase II Study of Pazopanib in Metastatic Merkel Cell Carcinoma

**Closed with Active Patients**

A randomised trial evaluating the VEGF inhibitor, Bevacizumab (Avastin®), as adjuvant therapy following resection of AJCC stage IIIB (T3bN0M0 & T4aN0M0), IIIC (T4bN0M0) and III (TxN1-3M0) cutaneous melanoma

A Randomized, Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy.
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Subjects with Previously Untreated Unresectable or Metastatic Melanoma.

A Phase III, randomised, open-label study comparing the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib to the BRAF inhibitor vemurafenib in subjects with unresectable (stage IIIc) or metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma

COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection

A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma

MEK114267, a phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma

An open-label, multicenter study to assess the safety of RO5185426 in patients with metastatic melanoma
Teaching and Education

Teaching and education is an important part of our work. Undergraduates from the University of Manchester regularly rotate through our service to gain experience and have completed audit projects linked to melanoma. In addition, we regularly have work experience students, either placed by the School of Oncology or as a result of direct contact out with Manchester.

Postgraduate education is an important responsibility. Specialist trainees from Dermatology and Palliative Care attend clinics for four months to get experience in melanoma, clinical trials and translational research. The Christie placement for specialist trainees in plastic surgery provides them with their principle experience and syllabus fulfilment in oncological management and surgery and the department attracts national applicants for a post-CCT fellow in oncological surgery and reconstruction.

We have 2 visiting Clinical Fellows, funded by commercial income and charitable donations.

Dr Lorigan is joint supervisor for three PhD students and a 4th was awarded her degree in 2013. In addition, we had our first Clinical Academic Trainee in 2014, and junior trainee with significant potential for research on a dedicated clinical and academic training programme.

We have run a number of educational meetings, detailed below:

1. **Surgical Management of Malignant Melanoma 2014**. This was a national meeting arranged by Mr Deemesh Oudit and held at the Christie.

2. **Annual ‘Focus on Melanoma’ meeting, London 2014**. Dr Lorigan is chair of Melanoma Focus charity and was also on the programme committee for this national meeting.

3. **Joint ESMO/ Christie Preceptorship in Immuno-oncology, Manchester, January 2015**. This is an international educational meeting, one of 4 to be held in Europe, the only one in the UK. Dr Lorigan and Prof Marais are the organisers

5. *Patient and carer open-access meeting*, Manchester Museum June 2013.